• / Free eNewsletters & Magazine
  • / My Account

High Risk

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Fitch Affirms Banesco USA's Ratings Following Downgrade of Venezuela-based BBU

    Fitch Affirms Banesco USA's Ratings Following Downgrade of Venezuela-based BBU

  2. UPDATE: Three reasons why Europe is the place to invest next year

    UPDATE: Three reasons why Europe is the place to invest next year

  3. Humana and United Hospital System Establish Accountable Care Agreement for Medicare Members in Wisconsin

    Humana and United Hospital System Establish Accountable Care Agreement for Medicare Members in Wisconsin

  4. From pariah to hero -- why Europe is where to invest next year

    From pariah to hero -- why Europe is where to invest next year

  5. Inovio Pharmaceuticals Initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers

    Inovio Pharmaceuticals Initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers

  6. Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections

    Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections

  7. UPDATE: Your house may be haunted by its past

    UPDATE: Your house may be haunted by its past

  8. UPDATE: This little-known report can hike your home insurance

    UPDATE: This little-known report can hike your home insurance

  9. UPDATE: FTSE 100 drops in broad-based losses, but Dixons Carphone outperforms

    UPDATE: FTSE 100 drops in broad-based losses, but Dixons Carphone outperforms

  10. -- Phase III Results from German Breast Group (GBG) Demonstrates Superior Activity in High Risk Early Breast Cancer for Nab-Paclitaxel (ABRAXANE®) VS. Solvent-Based Paclitaxel—

    -- Phase III Results from German Breast Group (GBG) Demonstrates Superior Activity in High Risk Early Breast Cancer for Nab-Paclitaxel (ABRAXANE®) VS. Solvent-Based Paclitaxel—

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.